Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 10, 2026Experimental and Molecular PathologyOpen Access

Biomarkers including CA-125 complement natriuretic peptides to improve AHF congestion assessment and risk stratification.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Natriuretic peptides provide only an indirect assessment of congestion and may have limited accuracy in acute heart failure.

Do biomarkers such as CA-125, ADM, sST2, and sCD146 improve congestion assessment and risk stratification in patients with acute heart failure?

Population

Patients with AHF across 39 studies

Comparison

Assessment of CA-125, ADM and derivatives, sST2, or sCD146

Design

Systematic review

Key result

Across 39 studies, biomarkers including CA-125, ADM, sST2, and sCD146 provided complementary information to natriuretic peptides, improving congestion assessment and risk stratification in AHF.

Authors

AAAndreea AsafteiACAlexandr CeasovschihMCMihai Constantin

Discussion

Loading...

Member takes

Overview

May refine acute HF management strategies; extends biomarker evidence for congestion and prognosis.

Key Points

  • This review aims to identify relevant biomarkers for assessing congestion and predicting outcomes in acute heart failure.
  • Conducted a systematic review of existing literature on biomarkers in acute heart failure.
  • Analyzed studies focusing on congestion assessment and prognostic implications of identified biomarkers.
  • Included various peer-reviewed articles and clinical trials related to the topic.
  • Various biomarkers were found to be significant in assessing congestion in acute heart failure.
  • Some biomarkers showed strong correlations with patient prognosis, indicating potential for clinical use.
  • Findings suggest that using these biomarkers can lead to better management strategies for acute heart failure patients.

Study Design

Type

Systematic Review

Structured PICO

Do biomarkers such as CA-125, ADM, sST2, and sCD146 improve congestion assessment and risk stratification in patients with acute heart failure?

P
Population
A systematic review of 39 studies evaluating the utility of CA-125, ADM, sST2, and sCD146 for congestion assessment and prognosis in patients with acute heart failure.
E
Exposure
Assessment of biomarkers: carbohydrate antigen 125 (CA-125), adrenomedullin (ADM) and its derivatives, soluble suppression of tumorigenicity-2 (sST2), and soluble cluster of differentiation 146 (sCD146)
O
Outcome
Associations with clinical, imaging, or laboratory markers of congestion and/or prognostic outcomes (mortality and rehospitalization)surrogate

Novel biomarkers including CA-125, ADM, sST2, and sCD146 offer complementary value to natriuretic peptides for assessing congestion and prognosis in acute heart failure.

Limitations

  • Larger prospective and interventional studies are required to define their role in routine clinical practice and in guiding decongestive strategies.
  • Larger prospective and interventional studies are required to define their role in routine clinical practice and in guiding decongestive strategies

Cite This Study

Asaftei et al. (2026) conducted a systematic review in Acute heart failure. Biomarkers (CA-125, ADM, sST2, sCD146) was evaluated on Associations with congestion and prognosis. Across 39 studies, biomarkers including CA-125, ADM, sST2, and sCD146 provided complementary information to natriuretic peptides, improving congestion assessment and risk stratification in AHF.

synapsesocial.com/papers/6a5090156eeac72a437a1860https://doi.org/10.1016/j.yexmp.2026.105063
View Full Paper
Ask AI
Bookmark
Share